[Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
Seventy three patients with hyperlipoproteinemia (HLP) type II and IV were divided into three groups and treated with different pharmaceuticals. The first group was treated with 300 mg Radecol daily, the second--with 750 mg Probucol and the third--with 600 mg Bezalip. Best results in the patients with HLP, type II A, as regards the effect on total cholesterol were obtained in those treated with Probucol, in type II B the results from the treatment with Radecol and Probucol are similar. In type IV HLP the reduction of triglycerides is best manifested in those treated with Bezalip. The tolerance and indications for the treatment of the patients with the three preparations are evaluated with a view to individualization of the medicamentous treatment.
D001629:Bezafibrate / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D004341:Drug Evaluation; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009540:Nicotinyl Alcohol / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol; D009540:Nicotinyl Alcohol; D011341:Probucol; D001629:Bezafibrate
Pokazaniia i lechebno vŭzdeĭstvie na niakoi khipolipidemichni sredstva pri bolni s khiperlipoproteinemii.